Overview

An Exploratory Clinical Study of GC012F Injection for Refractory gMG

Status:
WITHDRAWN
Trial end date:
2027-10-01
Target enrollment:
Participant gender:
Summary
This study is a single-arm, open-label early exploratory clinical trial designed to evaluate the safety, tolerability, and preliminary efficacy of GC012F injection in subjects with refractory GMG. Additionally, the study aims to assess the pharmacokinetic (PK), pharmacodynamic (PD) characteristics, and immunogenicity of GC012F injection in subjects.
Phase:
EARLY_PHASE1
Details
Lead Sponsor:
Zhejiang University
Collaborator:
Gracell Biotechnologies (Shanghai) Co., Ltd.